Navigation Links
Rowen White to White Cornea Gauge

ProductsRowen White to White Cornea Gauge
Company Rhein Medical, Inc.
Item Rowen White to White Cornea Gauge
Features 
Description A Set Of Corneal Gauges Allowing The Exact Outer Diameter Measurement Of A Cornea. Range Of 10.5mm To 13.0mm, With 0.25mm Increments. Easy And Quick To Use, With One-HandedOperation. Simply Dial The Desired Gauge And Place Over A Cornea For Confirmation Of Exact Corneal Diameter. Reusable, Autoclaveable, Made In The USA, Guaranteed For Life, And Available For A Surgical Evaluation Without Obligation.
Info Rhein Medical, Inc.
Customer Service: (800) 637-4346
Web site: http://www.rheinmedical.com

Related medicine products :

1. White long handle
2. Translucent White-Long
3. Long Handle Occluder - White
4. White-out
5. Illuminated PHOROPTOR Refracting Instrument - Minus Cylinder White
6. Illuminated PHOROPTOR Refracting Instrument - Plus Cylinder White
7. Ultramatic RX Master PHOROPTOR Refracting Instrument - Plus Cylinder White
8. White, Right
9. White Left
10. White, Universal
11. Sovereign with WhiteStar Cold Phaco Technology
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Curved shaft with flat 4.5 mm hook. Flat serrated handle with polished finish. Overall length: 5.3 inches....
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
This suture adjuster facilitates post operative suture adjustment of running sutures while decreasing the possibility of suture damage or breakage....
Medicine Products:
(Date:5/4/2015)... 2015 “ Food Cost Calculator ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... to manage and efficiently calculate food costs. , The restaurant ... fact, the industry has an estimated 1.8 trillion dollar impact ...
(Date:5/4/2015)... 2015 The Accreditation for ... first-ever congenital heart disease (CHD) standards for ... accreditation. Driven by the latest available clinical ... review of interventional procedures in pediatric patients ... “The ACE CHD Standards for PCCL Accreditation, ...
(Date:5/4/2015)... “St. Louis has long represented opportunity ... West,” so it is the perfect place for Zerorez ... Ben Litalien, Chief Development Officer for Zerorez. “We ... will provide veterans with a $10,000 discount on our ... have a number of Military Veterans in its ranks ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... Barbara Crone has joined Women’s Excellence in ... of the men, women and families who seek her care, initially ... for families in the home. , “When the ... if I could complete their care with the delivery of their ... mentor Nurse Midwife, I knew it was time for me to ...
Breaking Medicine News(10 mins):Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2
... Ustekinumab injections every 3 months a more convenient ... News) -- The drug ustekinumab has been shown to ... moderate-to-severe psoriasis in two studies published in this week,s ... by binding to two interleukins, proteins produced by the ...
... leadership in proposing prescription,drug marketing reform and transparency, ... believes,New York has a paramount interest in passing ... undue influence that,pharmaceutical companies have over prescribing decisions ... treatment they receive., The reforms include banning ...
... worldwide cancer incidence, researchers at the Moores Cancer Center ... Department of Family and Preventive Medicine have shown a ... ultraviolet B (UVB), and breast cancer. , UVB ... This form of vitamin D also is available through ...
... May 15 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... March 31, 2008. Pharmasset reported a net loss ... per share for the,quarter ended March 31, 2008, ...
... The following is a,statement from Larry Minnix, President ... Aging:, "Today,s GAO report points out yet again ... of nursing homes in this country. If,we want to ... need to,rethink our approach from the bottom up., ...
... Theranostics Health (THX) today,announced that it ... agreement with Duke University. This relationship will,provide ... technologies: Laser,Capture Microdissection (LCM) and Reverse Phase ... technologies provides a powerful,mechanism to accurately and ...
Cached Medicine News:Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8Health News:Theranostics Health Signs Research Collaboration Agreement 2
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... of the agreement, Isis is eligible to receive up ... $100 million up-front payment and a $55 million payment ... study in patients with compromised kidney function. Isis is ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5